NovaBay Pharmaceuticals is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market.  NovaBay has two distinct product categories: the NEUTROX™ family of products, led byAVENOVA™ for the eye care market, NEUTROPHASE® for wound care, and CELLERX™ for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE™. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome.  These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million.  NovaBay is gaining market traction with AVENOVA through its 35-medical direct sales representatives under veteran leadership.  AVENOVA is available for order in 90% of all pharmacies across the U.S. through distribution agreements with AmerisourceBergen, Cardinal Health and McKesson.